Abstract:BACKGROUND AND AIMS:Blood and/or liver fatty acid contents of healthy subjects and non-alcoholic fatty liver disease (NAFLD) patients have shown inconsistent associations. In addition, the results of randomized controlled trials (RCTs) in relation to the effects of n-3 polyunsaturated fatty acid (PUFA) supplementation on alanine aminotransferase (ALT), aspartate aminotransferase (AST), liver fat, triglyceride (TAG) and fasting glucose levels are inconsistent. The present study aimed to investigate the differences of fatty acid content in the blood and/or liver tissue between healthy subjects and NAFLD patients, and to quantify the benefits of n-3 PUFA therapy in NAFLD patients.METHODS:A systematic literature search was performed up to November 2016 using PubMed and Scopus databases. The differences of fatty acid content between cases and controls were calculated as weighted mean differences (WMD) by using a random-effects model. The intervention effects of RCTs were calculated as WMD for net changes in ALT, AST, liver fat, TAG and fasting glucose levels, respectively. Meta-regression with restricted maximum likelihood estimation was used to evaluate a potential linear relationship between confounding factors and effect sizes. Generalized least square was performed for dose-response analysis.RESULTS:Ten eligible case-control studies and 11 RCTs were included. The pooled estimates of case-control studies showed that blood and/or liver docosahexaenoic acid (DHA) content was significantly higher in the controls compared with cases. The pooled estimates of RCTs showed that n-3 PUFA supplementation significantly reduced the ALT (-7.53 U/L; 95% CI: -9.98, -5.08 U/L), ASL (-7.10 U/L, 95% CI: -11.67, -2.52 U/L) and TAG (-36.16 mg/dL, 95% CI: -49.15, -23.18 mg/dL) concentrations, and marginally reduced the liver fat content (-5.11%, 95% CI: -10.24, 0.02%, P = 0.051), but not fasting glucose. Dose-response analysis of RCTs showed that 1 g per day increment of eicosapentaenoic acid (EPA)+DHA was associated with a 3.14 U/L, 2.43 U/L, 2.74% and 9.97 mg/dL reduction in ALT (95% CI: -5.25, -1.02 U/L), AST (95% CI: -3.90, -0.90 U/L), liver fat (95% CI: -4.32, -1.16%) and TAG (95% CI: -14.47, -5.48 mg/dL) levels, respectively.CONCLUSIONS:The present meta-analysis provides substantial evidence that n-3 PUFA supplementation, especially DHA, has a favorable effect in treatment of NAFLD.

Alleviation of Fatty Liver by Alpha-Linolenic Acid

N-3 Polyunsaturated Fatty Acids in Phospholipid or Triacylglycerol Form Attenuate Nonalcoholic Fatty Liver Disease Via Mediating Cannabinoid Receptor 1/adiponectin/ceramide Pathway.

3-Acetyl-oleanolic acid ameliorates non-alcoholic fatty liver disease in high fat diet-treated rats by activating AMPK-related pathways

α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats

Pea Albumin Alleviates Oleic Acid-Induced Lipid Accumulation in LO2 Cells Through Modulating Lipid Metabolism and Fatty Acid Oxidation Pathways

Fatty Acid and Non-Alcoholic Fatty Liver Disease: Meta-analyses of Case-Control and Randomized Controlled Trials.

Oleic Acid Protects Saturated Fatty Acid Mediated Lipotoxicity in Hepatocytes and Rat of Non-Alcoholic Steatohepatitis.

Dietary Phosphatidylcholine Alleviates Fatty Liver Induced by Orotic Acid.

Effects of -Linolenic Acid Intake on Blood Lipid Profiles:A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Oils rich in α-linolenic acid independently protect against characteristics of fatty liver disease in the Δ6-desaturase null mouse

Lauric acid attenuates hepato-metabolic complications and molecular alterations in high-fat diet-induced nonalcoholic fatty liver disease in rats

Biochemical and Molecular Actions of Nutrients Dietary Conjugated Linoleic Acid Alleviates Nonalcoholic Fatty Liver Disease in Zucker ( fa / fa ) Rats 1

Effect of Oleoylethanolamide on Diet-Induced Nonalcoholic Fatty Liver in Rats

Dietary Conjugated Linoleic Acid Alleviates Nonalcoholic Fatty Liver Disease In Zucker (Fa/Fa) Rats

Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease

Vegetable oils rich in alpha linolenic acid allow a higher accretion of n-3 LCPUFA in the plasma , liver and adipose tissue of the rat

Comparative Analysis of EPA/DHA-PL Forage and Liposomes in Orotic Acid-Induced Nonalcoholic Fatty Liver Rats and Their Related Mechanisms

Eicosapentaenoic Acid-Containing Phosphatidylcholine Alleviated Lipid Accumulation in Orotic Acid-Induced Non-Alcoholic Fatty Liver

The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs

Oleanolic Acid Targets the Gut-Liver Axis to Alleviate Metabolic Disorders and Hepatic Steatosis.

Oleanolic Acid Alleviates ANIT-induced Cholestatic Liver Injury by Activating Fxr and Nrf2 Pathways to Ameliorate Disordered Bile Acids Homeostasis